Agios Pharmaceuticals, Inc. (LON:0HB0)
United Kingdom · Delayed Price · Currency is GBP · Price in USD | Market Cap | 1.41B -21.6% |
| Revenue (ttm) | 106.09M +214.4% |
| Net Income | -280.88M |
| EPS | -4.71 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 281 |
| Open | 31.36 |
| Previous Close | 30.99 |
| Day's Range | 31.21 - 31.90 |
| 52-Week Range | 22.40 - 45.81 |
| Beta | 0.63 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company’s PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of a... [Read more]
News
Agios Pharmaceuticals price target lowered to $48 from $50 at BofA
BofA lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $48 from $50 and keeps a Buy rating on the shares.
Agios Pharmaceuticals price target raised to $62 from $55 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Agios Pharmaceuticals (AGIO) to $62 from $55 and keeps a Buy rating on the shares. The firm sees the Aqvesme prescription trajectory…
Agios Pharmaceuticals price target lowered to $35 from $37 at Truist
Truist lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $35 from $37 and keeps a Buy rating on the shares. Q&A on the earnings call largely centered on…
Agios Pharmaceuticals Earnings Call Transcript: Q3 2026
Q3 revenue reached $55.4 million, more than 4x YoY, led by AQVESME. Sickle cell review now targets February 1, 2027 after an FDA REMS information request; launch readiness and the 2028 non-GAAP profitability target remain in focus.
Agios Pharmaceuticals Earnings release: Q3 2026
Agios Pharmaceuticals released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Agios Pharmaceuticals Slides: Q3 2026
Agios Pharmaceuticals has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 5, 2026.
Agios Pharmaceuticals Quarterly report: Q3 2026
Agios Pharmaceuticals has published its Q3 2026 quarterly earnings report on November 5, 2026.
Agios Pharmaceuticals reports Q3 EPS ($1.09), consensus ($1.23)
Reports Q3 revenue $55.4M, consensus $51.6M. Agios expects that cash, cash equivalents and marketable securities, together with anticipated product revenue and interest income, will provide the financ...
Agios Reports Third Quarter 2026 Financial Results and Provides Business Update
Mitapivat (PYRUKYND® and AQVESME®) delivered worldwide net revenues of $55.4 million in third quarter of 2026, more than four times the $12.9 million reported in third quarter of 2025 Strong U.S. dema...
Agios to Highlight Strength and Differentiation of Rare Hematology Portfolio with New Clinical Data for Mitapivat in Sickle Cell Disease and AG-236 in Polycythemia Vera at ASH 2026
Agios announces new clinical data across company's rare hematology portfolio that will be featured in oral and poster presentations during ASH 2026.
Agios FDA review delay just ‘timing setback,’ says H.C. Wainwright
H.C. Wainwright is surprised that the FDA extended the review period for Agios Pharmaceuticals (AGIO)’ mitapivat in sickle cell disease. The agency moved the drug’s action date by three months…
Agios Pharmaceuticals announces new PDUFA goal date for mitapivat sNDA
Agios Pharmaceuticals (AGIO) announced that the FDA has extended the Prescription Drug User Fee Act, or PDUFA, goal date for the supplemental New Drug Application, or sNDA, for mitapivat, an…
Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDA
FDA recently requested additional information to evaluate whether a REMS is necessary for mitapivat in sickle cell disease FDA classified Agios' response to the information request as a major amendmen...
Agios Pharmaceuticals assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao assumed coverage of Agios Pharmaceuticals (AGIO) with a Buy rating and $55 price target The firm believes the market is undervaluing the opportunity for mitapivat…
Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET
CAMBRIDGE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients wit...
Agios Pharmaceuticals price target lowered to $37 from $39 at Truist
Truist lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $37 from $39 and keeps a Buy rating on the shares as part of a broader research note previewing…
Agios Pharmaceuticals price target raised to $50 from $46 at BofA
BofA raised the firm’s price target on Agios Pharmaceuticals (AGIO) to $50 from $46 and keeps a Buy rating on the shares. Despite falling off all-time highs over the past…
Agios Pharmaceuticals price target raised to $52 from $46 at Citi
Citi raised the firm’s price target on Agios Pharmaceuticals (AGIO) to $52 from $46 and keeps a Buy rating on the shares. The firm views the Q2 report as strong…
Agios Pharmaceuticals price target raised to $55 from $52 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Agios Pharmaceuticals (AGIO) to $55 from $52 and keeps a Buy rating on the shares. The firm updated the company’s model post…
Agios Pharmaceuticals Transcript: Transcript
Q2 2026 saw strong commercial momentum with $44.7M in net revenue, robust AQVESME launch progress, and pipeline advances including FDA acceptance of mitapivat for sickle cell disease. The company ended the quarter with ~$1B in cash, supporting continued growth and R&D.
Agios Pharmaceuticals Quarterly report
Agios Pharmaceuticals has published a quarterly earnings report on July 30, 2026.
Agios Pharmaceuticals Slides
Agios Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on July 30, 2026.
Agios Pharmaceuticals reports Q2 EPS ($1.69), consensus ($1.66)
Reports Q2 revenue $44.75M, consensus $26.7M. Cash, cash equivalents and marketable securities were $964.8M as of June 30, 2026, compared to $1.2B as of December 31, 2025. “Our second-quarter performa...
Agios Pharmaceuticals Earnings release
Agios Pharmaceuticals released its earnings on July 30, 2026, summarizing the period's financial results.
Agios Reports Second Quarter 2026 Financial Results and Provides Business Update
Mitapivat (PYRUKYND® and AQVESME™) delivered worldwide net revenues of $44.7 million in the second quarter of 2026, compared to $12.5 million in the second quarter of 2025 Strong U.S. commercial launc...